Clinical Trials Logo

Stage IV Breast Cancer clinical trials

View clinical trials related to Stage IV Breast Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05025748 Completed - Clinical trials for Stage IV Breast Cancer

Ask Questions (ASQ):Implementation of a Communication Intervention

Start date: August 25, 2021
Phase: N/A
Study type: Interventional

This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.

NCT ID: NCT04298333 Completed - Clinical trials for Metastatic Breast Cancer

Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer

Start date: June 27, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the cumulative Maximum Tolerated Dose (MTD) and Minimum Efficient Dose (MED) of BP-C1 in the short-term treatment of metastatic breast cancer patients.

NCT ID: NCT03789019 Completed - Clinical trials for Metastatic Breast Cancer

BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment

Start date: February 22, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish an optimal treatment duration and tolerable cumulative dose for BP-C1 in the treatment of metastatic breast cancer patients who had previously undergone at least three lines of chemotherapy.

NCT ID: NCT03683147 Completed - Clinical trials for Stage IV Breast Cancer

Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer

Start date: December 13, 2017
Phase: N/A
Study type: Interventional

This randomized trial studies how well a mindfulness-based stress reduction program helps participants with breast cancer that has spread to other places in the body. A cancer diagnosis is a life-changing and highly stressful event for most people, often resulting in marked declines in quality of life both during and after treatment. There are approximately 3 million women living with a history of invasive breast cancer in the U.S., with at least 150,000 living with metastatic disease. Patient preferences suggest a high need for complementary and alternative medicine interventions to address these chronic symptoms. Mindfulness-based stress reduction programs may help women living with metastatic breast cancer manage symptoms related to cancer treatment and improve quality of life.

NCT ID: NCT03603197 Completed - Clinical trials for Metastatic Breast Cancer

BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer

Start date: June 5, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether BP-C1 is effective in the short-term treatment of metastatic breast cancer patients who have previously undergone at least three lines of chemotherapy.

NCT ID: NCT03455270 Completed - Breast Cancer Clinical Trials

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Start date: May 9, 2018
Phase: Phase 1
Study type: Interventional

This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader (SERD) alone and in combination with palbociclib, a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. The study is an open-label design, consisting of 3 parts: dose-finding portion including food effect (Part 1), G1T48 monotherapy expansion portion (Part 2), and G1T48 in combination with palbociclib expansion portion (Part 3). All parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 184 patients may be enrolled in the study.

NCT ID: NCT03364348 Completed - Clinical trials for Stage IV Breast Cancer

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Start date: October 30, 2017
Phase: Phase 1
Study type: Interventional

This trial studies the best dose and side effects of utomilumab (4-1BB agonist monoclonal antibody PF-05082566) with trastuzumab emtansine or trastuzumab in treating patients with HER2-positive breast cancer that has spread to other places in the body. Monoclonal antibodies, such as utomilumab, trastuzumab emtansine, and trastuzumab may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03222258 Completed - Clinical trials for Stage IV Breast Cancer

Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients

Start date: December 17, 2016
Phase:
Study type: Observational

This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study. Participants will be separated into different groups by their intentions for using palliative care. Every participant will carry out the questionnaire per 3 months. This cohort study will be ended a year after each participant enrolls. However, if the participant didn't survive during this study, the caregivers will be asked to fill out additional questionnaire after 3 months of the death.

NCT ID: NCT03139435 Completed - Clinical trials for Stage IV Breast Cancer

Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer

Start date: May 11, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer. Ultrasound may work better in diagnosing and detecting neuropathy in breast cancer patients treated with the chemotherapy drug called a taxane.

NCT ID: NCT03112668 Completed - Clinical trials for Stage IV Breast Cancer

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Start date: December 6, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage III-IV cancer and their partners. Learning how to accept negative thoughts and feelings and how to live in the present without worrying about the future or past may improve coping skills in patients with stage III-IV cancer and their partners.